Clinical trial NCT04753359: Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
Official title: Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Colorectal Cancer
Diet Habit
Lead sponsor: University of Illinois at Chicago
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2021-02-15
Enrollment: 232
Sex: ALL
Minimum age (years): 45
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This study is a four-arm RCT designed to test the effect of a weight-stable MedDiet alone (Med-A) lifestyle intervention, calorie restriction for WL with no diet composition change (WL-A) intervention, a MedDiet WL lifestyle intervention (WL-Med) compared to Control on BA metabolism, the gut microbiome, and gene expression in exfoliated intestinal epithelial cells. The study includes 1) screening potential subjects; 2) baseline assessment of diet, lifestyle behaviors (e.g., physical activity), anthropometrics, and blood and fecal sampling; 3) a four-arm RCT; and 4) mid-(month 3) and post-intervention (month 6) assessments.
Primary purpose: PREVENTION

Brief summary: A Mediterranean Diet (MedDiet), a largely plant-based dietary pattern, is relevant to CRC prevention and microbial production of anti-cancer metabolites in observational studies. A MedDiet can shift BA metabolism as shown in primates and when combined with calorie restriction, shows superior adherence and weight control in humans, given its palatability. To date, no studies have tested in an RCT the effects of a MedDiet alone (MedA), WL through lifestyle intervention (WL-A) or a calorie-restricted MedDiet for WL (WL-Med) on the BA-gut microbiome axis and its relevance to CRC prevention among AAs. A multidisciplinary team combining expertise in psychology, nutrition, microbiology, molecular cell biology, computational biology, medicine and biostatistics, proposes to conduct a four-arm RCT in which 232 obese AAs, 45-75 years old complete one of the following 6-month interventions: Med-A, weight stable; WL-A, calorie restriction with no diet pattern change; WLMed; or Control. The investigators will use samples and data collected at baseline, mid-study (month-3) and post-intervention to compare the effects of the interventions on 1) Concentration and composition of circulating and fecal BAs; 2) Gut microbiota and metabolic function; and 3) Gene expression profiles of exfoliated intestinal epithelial cells.

Detailed description: Colorectal cancer (CRC) is associated with multiple risk factors including, obesity, low fiber diets, and diets high in animal protein and saturated fat (SFat). African Americans (AAs) have a higher prevalence of these risk factors and they have the highest incidence of CRC and related mortality. These multiple risk factors are also linked to higher circulating and fecal bile acids (BA) and a shift in BA amino acid conjugation from glycine to taurine. These BA-related changes can alter the composition, structure, and metabolic activity of the gut microbiota, fostering conditions for gut bacteria to expand and metabolize taurine-conjugated BAs to genotoxic hydrogen sulfide (H2S) and the tumor promoter, deoxycholic acid (DCA); a colonic milieu conducive to the formation of CRC. The investigators have shown that the abundance of H2S-producing bacteria is significantly higher in the colon of AAs compared to non-Hispanic whites (NHWs) and is a defining feature among AA CRC cases implicating these bacteria as contributors to CRC development in a race-dependent manner. Moreover, the microbial difference is associated with higher intake of SFat and animal protein in AAs, providing a pivotal intervention target. The investigators hypothesize that targeting the BA-gut microbiome axis to suppress abundance, growth and metabolic activity of H2S and DCA producing bacteria through diet and weight loss (WL) may reduce CRC risk, especially among AAs. A Mediterranean Diet (MedDiet), a largely plant-based dietary pattern, is relevant to CRC prevention and microbial production of anti-cancer metabolites in observational studies. A MedDiet can shift BA metabolism as shown in primates and when combined with calorie restriction, shows superior adherence and weight control in humans, given its palatability. To date, no studies have tested in an RCT the effects of a MedDiet alone (MedA), WL through lifestyle intervention (WL-A) or a calorie-restricted MedDiet for WL (WL-Med) on the BA-gut microbiome axis and its relevance to CRC prevention among AAs. Our multidisciplinary team combining expertise in psychology, nutrition, microbiology, molecular cell biology, computational biology, medicine and biostatistics, propose to conduct a four-arm RCT in which 232 obese AAs, 45-75 years old complete one of the following 6-month interventions: Med-A, weight stable; WL-A, calorie restriction with no diet pattern change; WLMed; or Control. The investigators will use samples and data collected at baseline, mid-study (month-3) and post-intervention to compare the effects of the interventions on 1) Concentration and composition of circulating and fecal BAs; 2) Gut microbiota and metabolic function; and 3) Gene expression profiles of exfoliated intestinal epithelial cells. The investigators approach is strong given the multidisciplinary team, use of evidence-based lifestyle interventions, and sophisticated -omics analyses to examine crosstalk between diet/WL, gut microbiome, and host intestinal physiology. If successful, this study could have profound public health impact on CRC risk among AAs and other high-risk populations, that would translate into timely dissemination opportunities.

Eligibility criteria: Inclusion Criteria:

* Men and women 45-75 years of age
* Self-identify as AA
* BMI 30-50 kg/m2
* Willingness to participate in all procedures including maintaining weight/current physical activity if randomized to Med-A/Control
* Willingness and ability to provide informed consent
* Willingness to be randomized
* Understands English
* Has access to a phone
* Plans to reside in Chicago for the next 8-10 months.

Exclusion Criteria:

* renal disease
* autoimmune disorders
* immunodeficiency
* malabsorptive disorders
* significant gastrointestinal and/or hepatic diseases
* severe ischemic heart disease
* severe pulmonary disease
* history of bariatric surgery
* alcohol abuse (\> 50 grams/day)
* illicit drug abuse (other than marijuana based on self-report)
* combustible tobacco use
* uncontrolled diabetes based on HbA1c\>9.0%
* eating disorder
* cancer treatment within the past 12 months
* history of CRC
* genetic predisposition to CRC (e.g., Lynch syndrome)
* weight \> 450 lbs. (weight limitation of the DXA scanner)
* currently adhering to a MedDiet based on a diet screener
* self-reported WL \> 3% in the past 12 months
* currently on a WL diet or actively involved in a formal WL program (e.g., Weight Watchers)
* food allergies that would interfere with adopting a MedDiet
* antibiotic use in the past 3 months
* night-shift work
* regular use (i.e., ≥ 3 times per week) of prebiotics/probiotics/synbiotics, dietary fiber supplements, or laxatives,
* Gait disorder
* currently pregnant
* active Covid-19 infection within 6 weeks of recruitment/data collection.

Primary outcomes:
measure: Circulating and fecal bile acids
timeFrame: baseline
measure: Circulating and fecal bile acids
timeFrame: 3 month
measure: Circulating and fecal bile acids
timeFrame: 6 month
measure: Gut microbiota for metabolic function
timeFrame: baseline
measure: Gut microbiota for metabolic function
timeFrame: 3 month
measure: Gut microbiota for metabolic function
timeFrame: 6 month
measure: Gene expression
timeFrame: baseline
measure: Gene expression
timeFrame: 3 month
measure: Gene expression
timeFrame: 6 month
measure: Exfoliated intestinal epithelial cell transcriptomics
timeFrame: Baseline
measure: Exfoliated intestinal epithelial cell transcriptomics
timeFrame: 3 months
measure: Exfoliated intestinal epithelial cell transcriptomics
timeFrame: 6 months
Secondary outcomes:
measure: Body weight
timeFrame: baseline
measure: Body weight
timeFrame: 3 month
measure: Body weight
timeFrame: 6 month
measure: Body mass index
timeFrame: baseline
measure: Body mass index
timeFrame: 3 month
measure: Body mass index
timeFrame: 6 month
measure: Mediterranean Diet Adherence
timeFrame: Baseline
measure: Mediterranean Diet Adherence
timeFrame: Month 1
measure: Mediterranean Diet Adherence
timeFrame: Month 2
measure: Mediterranean Diet Adherance
timeFrame: Month 3
measure: Mediterranean Diet Adherence
timeFrame: Month 4
measure: Mediterranean Diet Adherence
timeFrame: Month 5
measure: Mediterranean Diet Adherence
timeFrame: Month 6
measure: Physical activity
timeFrame: Baseline
measure: Physical activity
timeFrame: 3 month
measure: Physical activity
timeFrame: 6 month
measure: Total and regional body composition (fat and muscle)
timeFrame: baseline
measure: Total and regional body composition (fat and muscle)
timeFrame: 3 month
measure: Total and regional body composition (fat and muscle)
timeFrame: 6 month
measure: Circulating cytokines
timeFrame: Baseline
measure: Circulating cytokines
timeFrame: 3 month
measure: Circulating cytokines
timeFrame: 6 month
measure: Fasting glucose
timeFrame: Baseline
measure: Fasting glucose
timeFrame: 3 month
measure: Fasting glucose
timeFrame: 6 month
measure: Fasting insulin
timeFrame: Baseline
measure: Fasting insulin
timeFrame: 3 month
measure: Fasting insulin
timeFrame: 6 month
Other outcomes:
measure: Adverse events
timeFrame: Through study completion, an average of 6 months
measure: Psychosocial health
timeFrame: Baseline
measure: Psychosocial health
timeFrame: 3 month
measure: Psychosocial health
timeFrame: 6 month
measure: Medication use
timeFrame: baseline
measure: Medication use
timeFrame: 3 month
measure: Medication use
timeFrame: 6 month
measure: Bowel habits
timeFrame: baseline
measure: Bowel habits
timeFrame: 3 month
measure: Bowel habits
timeFrame: 6 month
Locations:
city: Chicago
country: United States
facility: University of Illinois at Chicago
state: Illinois
Study officials:
affiliation: University of Illinois at Chicago
name: Lisa Tussing-Humphreys, PhD, RD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Illinois at Chicago
name: Marian Fitzgibbon, PhD
role: PRINCIPAL_INVESTIGATOR
References: